{"id":"W1926992252","doi":"10.1200/jco.2012.30.15_suppl.4519","title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Interim analysis; Docetaxel; Adverse effect; Randomized controlled trial; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008140205,0.001091896,0.00189481,0.0004079636,0.0003932755,0.001003698,0.0006364083,0.001095139,0.006300228],"category_scores_gemma":[0.004470366,0.000304812,0.002559262,0.0003736752,0.0004559754,0.0005972306,0.0004328722,0.002154396,0.0007094276],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006518004,"about_ca_system_score_gemma":0.001064069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004676908,"about_ca_topic_score_gemma":0.0008055665,"domain_scores_codex":[0.9974594,0.001556184,0.0001871085,0.0002470652,0.0003042629,0.0002460433],"domain_scores_gemma":[0.9951031,0.001620956,0.001527317,0.0002158156,0.0005117413,0.001020988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9247606,0.00799442,0.01830888,0.0009744222,0.004228802,0.0000737642,0.00004784992,0.00140353,0.00361,0.0001663977,0.004819995,0.03361126],"study_design_scores_gemma":[0.5782567,0.2437623,0.1541986,0.000194274,0.008216606,0.0004004846,0.00006456365,0.002344048,0.004900942,0.0007726355,0.006814028,0.00007484138],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529454,0.01161143,0.001399506,0.0008875817,0.0003384524,0.004181875,0.01979731,0.0001332271,0.00870521],"genre_scores_gemma":[0.9814578,0.001199329,0.0009263718,0.0007172301,0.0002191147,0.002777653,0.01032498,0.00003281892,0.002344819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008140205,"threshold_uncertainty_score":0.04305005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2806508688257405,"score_gpt":0.5250663325708724,"score_spread":0.2444154637451319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}